Hugh C. Rayner

Dr. Hugh C. Rayner

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
HRHugh C. Rayner
Hugh C. Rayner
MLMaria Larkina
Maria Larkina
MWMia Wang
Mia Wang
MGMatthew Graham-Brown
Matthew Graham-Brown
SVSabine N. van der Veer
Sabine N. van der Veer
RPRonald L. Pisoni
Ronald L. Pisoni
Background and objectives Uremic pruritus in patients on hemodialysis is associated with depression, lower quality of life, and mortality. We studied the prevalence, awareness, and treatment of pruritus to assess how well this important condition is currently managed internationally. Design, setting, participants, & measurements Data from 35,452 patients on hemodialysis in up to 17 countries from the Dialysis Outcomes and Practice Patterns Study were analyzed to describe pruritus prevalence from 1996 to 2015. Data from 6256 patients and 268 medical directors in 17 countries in 2012–2015 were analyzed to describe predictors, effects, medical directors’ awareness, and treatment of pruritus. Results Patients very much or extremely bothered by itching declined from 28% in 1996 to 18% in 2015. In 2012–2015, among patients nearly always or always bothered by itching, pruritus had a major effect on work and social life; 18% used no treatment for pruritus, and 17% did not report itching to health care staff. In total, 69% of medical directors underestimated the prevalence of pruritus in their unit. Managing high serum phosphorus and low Kt/V was ranked as the most important intervention, but no relationship was found between these factors and pruritus; 57% of medical directors used oral antihistamines for first-line chronic treatment of pruritus. Gabapentin was used by 45% as first-, second-, or third-line treatment. Nalfurafine was only used in Japan. Conclusions The prevalence of pruritus in people on hemodialysis is decreasing but remains underestimated. Large numbers of patients on hemodialysis with severe pruritus do not receive treatment. There is wide variation in the use of unlicensed medications for the treatment of pruritus. These data provide a benchmark for initiatives to improve the management of uremic pruritus. Multimedia This article contains multimedia at https://vimeo.com/49458473 This article contains multimedia at vimeo.com/49455976

1 July 2014 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
HRHugh C. Rayner
Hugh C. Rayner
LZLindsay Zepel
Lindsay Zepel
DFDouglas S. Fuller
Douglas S. Fuller
HMHal Morgenstern
Hal Morgenstern
AKAngelo Karaboyas
Angelo Karaboyas
BRBruce M. Robinson
Bruce M. Robinson

1 May 2001 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
JLJane Little
Jane Little
AIAdam Irwin
Adam Irwin
TMTim Marshall
Tim Marshall
HRHugh C. Rayner
Hugh C. Rayner
SSStephen Smith
Stephen Smith

28 March 2013 in Nephron Clinical Practice
Verified
Journal Article
Open access
PDF file
HRHugh C. Rayner
Hugh C. Rayner
JBJyoti Baharani
Jyoti Baharani
SSSteve Smith
Steve Smith
VSVijayan Suresh
Vijayan Suresh
IDIndranil Dasgupta
Indranil Dasgupta
Background: Pruritus (skin irritation or itching) is common in patients with chronic kidney disease (CKD) stages 4 and 5. It is associated with disrupted sleep, reduced quality of life, depression and increased mortality. A video of a patient describing the symptoms is at vimeo.com/49458473. Methods: We used gabapentin or pregabalin in 71 consecutive patients, 82% male. 25 had CKD stage 4 or 5, median eGFR = 17, range 9-30; 40 were on haemodialysis; 6 on peritoneal dialysis. Median itch severity score out of 10 = 8, range 6-10; median duration of itching = 6 months, range 0.5-240. Serum calcium ≤2.60 mmol/l (≤10.4 mg/dl) in 87% patients, phosphate ≤1.8 mmol/l (≤5.6 mg/dl) in 75%. 63% had used antihistamines and not gained relief. Starting dose of gabapentin 100 mg after dialysis or daily. Patients intolerant of gabapentin were offered pregabalin, starting dose 25 mg after dialysis or daily. Results: Gabapentin relieved itching in 47 patients (66%). A video of a patient describing the effect is at vimeo.com/49455976. 26 patients (37%) suffered side effects from gabapentin. Of 21 patients who stopped gabapentin due to side effects, 16 started pregabalin. Pregabalin relieved itching in 13 patients (81%). In total, gabapentin or pregabalin relieved itching in 60 patients (85%), median follow-up 2 months (range 1-8 months). Median itch severity out of 10 reduced from 8 to 1. Conclusions: Gabapentin or pregabalin relieved itching in 85% of 71 consecutively treated CKD patients. Patients should be advised about side effects and the drug initiated at a low dose. Patients intolerant of gabapentin may tolerate pregabalin.

1 January 2010 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
HRHugh C. Rayner
Hugh C. Rayner
RPRonald L. Pisoni
Ronald L. Pisoni

10 December 2013 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
HRHugh C. Rayner
Hugh C. Rayner
JBJyoti Baharani
Jyoti Baharani
IDIndranil Dasgupta
Indranil Dasgupta
VSVijayan Suresh
Vijayan Suresh
RTRobert M. Temple
Robert M. Temple
SSSteve A. Smith
Steve A. Smith
The number of patients starting renal replacement therapy (RRT) is increasing in England, as it is worldwide. Improvements in the management of chronic kidney disease (CKD) across communities to alter this trend are a public health priority. We have prospectively studied changes in the incidence and modality of treatment for end-stage renal disease following the introduction of a CKD management programme in the West Midlands region of England. Nephrology service to approximately 700 000 adult population of mixed ethnicity in urban and suburban areas, many with social deprivation. The programme was introduced in stages between 2003 and 2006 and comprised primary care education and financial incentives, personal clinical reports written directly to patients following every consultation, routine laboratory estimated glomerular filtration rate (eGFR) reporting, eGFR graph surveillance to identify and monitor patients at risk, multidisciplinary pre-RRT care and conservative care. Prevalent patients: 10 552 with CKD and 8509 without CKD with diabetes. Outcomes: access to nephrology care, trends in RRT incidence and starting modality, place of death without RRT. Incident count was adjusted for changes in the local adult population recorded in national censuses. Ninety-one per cent of patients aged ≥75 years with incident CKD stage 5 were known to a nephrologist. The population-adjusted incident RRT rate peaked in 2005 and then declined; the proportion starting with transplant, peritoneal dialysis or haemodialysis by arterio-venous fistula increased to 63% by 2012 (P = 0.001 versus 2005). Fifty-two per cent of patients receiving planned conservative care without dialysis died out of hospital. Following the introduction of a community-wide systematic CKD management programme, the population-adjusted incidence of RRT reduced, modality of initiation of RRT improved and a majority of patients receiving planned conservative care without dialysis died out of hospital.